){kind=logo}
Loeb & Loeb LLP is proud to sponsor the American Conference Institute's (ACI's) Advanced Summit of Life Sciences Patents where partner Mark E. Waddell will be co-chairing and speaking on a panel titled "Bracing for the Fallout from Inducement and Divided Infringement on Method of Treatment Claims for Pharmaceutical, Biotechnology, and Diagnostic Patents".
From the conference website:
Amidst crisis over §101 patentability and fears of an anti-patent climate, be a part of the premier life sciences intellectual property forum designed to provide you with the necessary skills to adapt to rapidly evolving industry standards.
Facing a double whammy of challenges in both the Federal Courts and the USPTO, life sciences patents have never been more vulnerable.
Decisions like Myriad and Prometheus have left specific types of patents subject to an onslaught of challenges, while decisions like Gilead and developments in PTO procedures have left entire patent portfolios hanging in the balance. Attend this event and walk away with tailored patent strategies you can immediately incorporate into your practice regarding §101 patentability, double patenting type obviousness, and written description and indefiniteness challenges.
Our accomplished faculty — a veritable “Who’s Who” of the life sciences patent bar — have united to provide comprehensive updates and strategic solutions to protect life sciences patents.
In-house representatives from Merck, Novartis, Biogen, Roche, and many more will share the methods that have worked for them in recent battles, and provide specific advice to protect your patent portfolio cost-effectively. Furthermore, this year’s conference features a new session in which former leaders from the USPTO and the Federal Circuit – including David Kappos and The Honorable Paul Michel – discuss patentability and the role of both agencies in the future of continued investment in life sciences R&D.
From the conference website:
Amidst crisis over §101 patentability and fears of an anti-patent climate, be a part of the premier life sciences intellectual property forum designed to provide you with the necessary skills to adapt to rapidly evolving industry standards.
Facing a double whammy of challenges in both the Federal Courts and the USPTO, life sciences patents have never been more vulnerable.
Decisions like Myriad and Prometheus have left specific types of patents subject to an onslaught of challenges, while decisions like Gilead and developments in PTO procedures have left entire patent portfolios hanging in the balance. Attend this event and walk away with tailored patent strategies you can immediately incorporate into your practice regarding §101 patentability, double patenting type obviousness, and written description and indefiniteness challenges.
Our accomplished faculty — a veritable “Who’s Who” of the life sciences patent bar — have united to provide comprehensive updates and strategic solutions to protect life sciences patents.
In-house representatives from Merck, Novartis, Biogen, Roche, and many more will share the methods that have worked for them in recent battles, and provide specific advice to protect your patent portfolio cost-effectively. Furthermore, this year’s conference features a new session in which former leaders from the USPTO and the Federal Circuit – including David Kappos and The Honorable Paul Michel – discuss patentability and the role of both agencies in the future of continued investment in life sciences R&D.
-
Co-Chair, Life Sciences; Chair, Patent Litigation & Counseling